Skip to content
Search

Latest Stories

What becoming an RPS Fellow means for Thorrun Govind

What becoming an RPS Fellow means for Thorrun Govind

This RPS fellowship comes at a particularly significant time for Thorrun, who has recently taken on a national leadership role with the Law Society

Pharmacist and healthcare lawyer Thorrun Govind has been designated as a Fellow of the Royal Pharmaceutical Society (RPS) for her exceptional contributions to the pharmacy profession.

The RPS Fellowship is awarded to members who have made an outstanding original contribution to the advancement of pharmaceutical knowledge or attained distinction in the science, practice, profession, or history of pharmacy.


Speaking to Pharmacy Business, Thorrun expressed feeling “deeply honoured and humbled” to receive the title.

“This feels like the culmination of years of hard work, dedication, and passion for the pharmacy profession,” she said.

As a trusted national commentator on health issues, Thorrun regularly appears on platforms such as the BBC, Sky, ITV, Talk TV, and Times Radio, and contributes to print media.

However, she acknowledges that her journey as a young pharmacist has not been without its challenges and obstacles.

“There are many people behind the scenes who support me in my endeavours, and I am incredibly appreciative of their unwavering support and encouragement.

“This fellowship is not just a personal achievement but a testament to the collective efforts of my family, pharmacy and legal colleagues, mentors, and the broader community who have believed in me and my vision,” she said.

Thorrun’s advocacy for pharmacy began long before she qualified as a pharmacist and became chair of the Royal Pharmaceutical Society’s English Pharmacy Board.

She views this recognition as a validation of those early efforts and the journey she has undertaken.

Thorrun, who is a practising solicitor in the regulatory and professional conduct team at Brabners LLP, also takes pride in being able to assist pharmacists in a legal capacity.

“This dual role enables me to bridge the gap between pharmacy and law, ensuring that pharmacists are well-represented and supported in all aspects of their professional lives,” she stated.

Asked what this recognition means for her career, Thorrun said: “It validates my efforts and commitment to advancing the pharmacy profession and I will continue to engage with the next generation of pharmacists.

Thorrun also credits her background in media and law for shaping her career.

She explained: “The skills and knowledge I have gained in these areas enable me to effectively communicate complex information to the public and advocate for policy changes that benefit both pharmacists and patients.

“This recognition motivates me to continue striving for excellence and innovation in my work, ensuring that I continue to make a meaningful impact on the profession and the communities we serve,” she added.

This recognition is particularly significant now as Thorrun has recently embarked on a national leadership role with the Law Society.

“I will continue to share insights from both professions to benefit each field,” she added.

More For You

How to leverage data to drive pharmacy growth

Adele Curran, chief operating officer at Real World Analytics (RWA) Pharmacy.

Pharmacy challenges: How data can help spot the ‘elephant in the room’

Adopting new technologies is vital for moving pharmacy forward — but are you fully harnessing the data these tools generate?

“Being able to utilise, manage, and interpret the data these technologies provide can help add more value to your business,” said Adele Curran, chief operating officer at Real World Analytics (RWA) Pharmacy, while speaking at the recent Pharmacy Business Conference.

Keep ReadingShow less
Branded OTC products can boost pharmacy revenue and promote self-care, says PAGB CEO

Michelle Riddalls

How branded OTC products can help struggling community pharmacies - PAGB chief explains

Branded over-the-counter (OTC) products could play a vital role in promoting self-care and supporting the sustainability of community pharmacies, said Michelle Riddalls, CEO of PAGB – the consumer healthcare association – during the recent Pharmacy Business Conference.

Riddalls emphasised that OTC medicines not only enable consumers to better manage their health through self-care but also offer pharmacies an opportunity to increase revenue, particularly during a time of mounting financial pressure.

Keep ReadingShow less
How Peptides Are Transforming Modern Drug Development

Modern Drug Development

How Peptides Are Transforming Modern Drug Development

The pharmaceutical industry is rapidly evolving, embracing new technologies and methodologies. Peptides are emerging as a crucial component in this transformation, offering innovative solutions to drug development. This shift is not only reshaping how drugs are discovered but also enhancing their efficacy and safety.

In recent years, the pharmaceutical landscape has undergone significant changes, driven by advancements in technology and scientific understanding. One of the most promising areas of innovation is the use of peptides in drug development. These short chains of amino acids have proven to be versatile tools, capable of targeting specific cells or molecules with high precision. In this context, certain bpc 157 peptide research peptides have been highlighted for their potential applications in various therapeutic areas, showcasing the promise that peptides hold for modern pharmaceutical studies.

Keep ReadingShow less
Off-patent medicines could save NHS millions—but only if UK remains attractive to suppliers - BGMA

BGMA chief executive Mark Samuels urges government to back off-patent medicines ahead of Life Sciences Plan release.

UK risks losing millions in NHS savings without stronger support for generics - BGMA

The British Generic Manufacturers Association (BGMA) has called on the government to create a more supportive environment for the generics and biosimilars sector, warning that the UK risks missing out on significant NHS savings arising from new off-patent medicines.

According to the BGMA, 31 medicines are due to lose patent protection between January and June 2025, with a further 28 set to follow in the second half of the year.

Keep ReadingShow less
Support for generic medicines manufacturers key to affordable healthcare- Teva UK director

Teva UK sounds alarm on accelerating consolidation of critical generic medicines

Photo credit: gettyimages

Exclusive: Teva UK calls for inclusion of generic manufacturers in policy talks

A healthy and vibrant generics marketplace supports not only patients but also contributes billions of pounds in savings to the drugs bill. However, growing pressures on generic medicine manufacturers could threaten this vital part of the healthcare ecosystem, warns Ryan Ruscoe, senior director of generics and OTC at Teva UK.

Speaking exclusively to Pharmacy Business, Ruscoe stressed the urgent need to address supply chain vulnerabilities, particularly for critical generic medicines.

Keep ReadingShow less